瑞格國際生技股份有限公司

Establishment status

Already set up (2006-07-10)

Domain

Cell Therapy
Precision Medicine
Biological agent

Registration place

Taiwan

Company size

1~10人

Capital amount

$2.3億 TWD (≈$7.3M USD)

The amount of funds raised this time

$2.1億 TWD (≈$6.8M USD)

Introduction

Regimmune is an innovative new drug company established in Japan by spinning out patented technology for designing immunotherapy. Aiming at both therapeutic areas of organ transplantation and solid tumor, Regimmune has achieved a major milestone for its first pipeline. Recently, the company is bringing some new pipelines from Japan to enrich its clinical assets and shareholder's value as well. Regimmune is planning to be listed in Taiwan's "Emerging Stock Market" in 2025.